Printer Friendly

MOLECULAR BIOSYSTEMS ANNOUNCES LICENSE OF ITS ANTISENSE PATENTS

 MOLECULAR BIOSYSTEMS ANNOUNCES LICENSE OF ITS ANTISENSE PATENTS
 SAN DIEGO, Sept. 22 /PRNewswire/ -- Molecular Biosystems Inc. (NYSE: MB) (MBI) announced today that it has granted a license for its pioneering U.S. and foreign patents for antisense technology to Isis Pharmaceuticals Inc. (NASDAQ: ISIP) of Carlsbad, Calif. The license grants Isis the right to nonexclusive worldwide use of its patents for all purposes in exchange for a license fee, annual maintenance fees and royalties to MBI. The specific terms of the license were not disclosed.
 MBI's European patent issued in April 1992 and contained broad claims covering basic antisense compounds and techniques(A). A patent with narrower claims issued in the United States in June 1991, but the broad claims remain pending with the U.S. Patent and Trademark Office, and MBI is prosecuting them diligently. The priority date for MBI's antisense patent estate is 1981, the year its first U.S. applications was filed.
 "The early priority date of the patent estate, combined with breadth of the issued European and pending U.S. claims, means that MBI possesses a dominant antisense patent estate," commented Kenneth J. Widder, M.D., MBI's chairman and chief executive officer. "We are pleased to have reached an early and amicable agreement with Isis, a leading company in antisense research." He noted that MBI is in discussions with other companies interested in acquiring an antisense license from MBI.
 Widder added that MBI would shortly begin contacting all companies known or believed to be working in the antisense field to alert them to MBI's patent estate and to the availability of a non- exclusive license. While he expressed the hope that companies whose products and activities fall within the scope of MBI's patents would enter into such licenses, he affirmed that "MBI will aggressively protect its patent position in all jurisdictions. If necessary, MBI will prosecute infringers."
 Molecular Biosystems Inc., based in San Diego, is a leader in the development and manufacturing of contrast agents for medical imaging, including ultrasound, magnetic resonance imaging and computerized tomography. Once approved, its flagship product, Albunex(R), will be marketed and distributed worldwide by MBI's partners, including Mallinckrodt Medical Inc. (IMCERA Group, NYSE: IMA) in the United States, Shionogi & Co. Ltd. in Japan, and Hafslund Nycomed AS (NYSE: HN) in Europe. MBI's shares are listed on the New York Stock Exchange under the symbol "MB."
 (A) "Antisense" generally describes a therapeutic technique whereby the manufacture of certain disease-related proteins in a cell is blocked or otherwise regulated. Proteins are manufactured through information provided by the molecular sequences of certain strands of deoxyribonucleic acid ("DNA") in the genes in the nucleus of a living cell. The information is in turn provided to messenger ribonucleic acid ("mRNA") compounds, which transport it to the protein-producing locations in the cell. "Antisense" compounds are pieces of synthetic DNA which hybridize (bind) with targeted mRNA strands, blocking their ability to transfer molecular information -- the so-called "sense" function -- and preventing formation of the undesirable proteins.
 -0- 9/22/92
 /CONTACT: Beth Field Wallace, investor relations, Molecular Biosystems, 619-452-0681, ext. 2212/
 (MB ISIP) CO: Molecular Biosystems Inc.; Isis Pharmaceuticals Inc. ST: California IN: MTC SU:


LS-JB -- SD001 -- 2096 09/22/92 10:34 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 22, 1992
Words:536
Previous Article:I-FLOW CORP. FILES FOR FDA PERMISSION TO MARKET NEW DRUG DELIVERY SYSTEM
Next Article:A&W BRANDS, INC. AND PEPSI-COLA INTERNATIONAL ASIA DIVISION SIGN AGREEMENT TO BOTTLE AND DISTRIBUTE A&W BRANDS PRODUCTS IN ASIA
Topics:


Related Articles
MOLECULAR BIOSYSTEMS ACQUIRES LICENSE TO CT IMAGING AGENT TECHNOLOGY
GEN-PROBE AND MOLECULAR BIOSYSTEMS SETTLE PATENT LITIGATION
CALGENE AND MONSANTO EXECUTE BROAD CROSS LICENSE AGREEMENTS
ImaRx PHARMACEUTICAL CORP. FILES SUIT AGAINST MOLECULAR BIOSYSTEMS INC. OVER TRADE SECRETS
CALGENE SIGNS ANTISENSE PATENT LICENSE WITH THE FRED HUTCHINSON CANCER RESEARCH CENTER
Genzyme Molecular Oncology Licenses Antisense Cancer Rights to Isis Pharmaceuticals.
Pharmacopeia, PE Biosystems and Becton, Dickinson Collaborate to Advance High-Throughput Screening Technology.
Isis Pharmaceuticals enters into agreement with Pfizer.
Isis license functional genomics patents to atugen.
Ambion and Applied Biosystems Combine siRNA and Real-Time PCR Products.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters